Myeloid Heme Oxygenase-1 Regulates the Acute Inflammatory Response to Zymosan in the Mouse Air Pouch by Brines, Rita et al.
Research Article
Myeloid Heme Oxygenase-1 Regulates the Acute Inflammatory
Response to Zymosan in the Mouse Air Pouch
Rita Brines, Laura Catalán, Maria José Alcaraz , and Maria Luisa Ferrándiz
Instituto Interuniversitario de Investigación de Reconocimiento Molecular y Desarrollo Tecnológico (IDM), Universitat Politècnica de
València, Universitat de València, Av. Vicent A. Estellés, s/n, Burjassot, 46100 Valencia, Spain
Correspondence should be addressed to Maria José Alcaraz; maria.j.alcaraz@uv.es
Received 29 June 2017; Revised 3 January 2018; Accepted 11 January 2018; Published 11 February 2018
Academic Editor: Qingping Feng
Copyright © 2018 Rita Brines et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Heme oxygenase-1 (HO-1) is induced by many stimuli to modulate the activation and function of different cell types during innate
immune responses. Although HO-1 has shown anti-inflammatory effects in different systems, there are few data on the
contribution of myeloid HO-1 and its role in inflammatory processes is not well understood. To address this point, we have
used HO-1M-KO mice with myeloid-restricted deletion of HO-1 to specifically investigate its influence on the acute inflammatory
response to zymosan in vivo. In the mouse air pouch model, we have shown an exacerbated inflammation in HO-1M-KO mice
with increased neutrophil infiltration accompanied by high levels of inflammatory mediators such as interleukin-1β,
tumor necrosis factor-α, and prostaglandin E2. The expression of the degradative enzyme matrix metalloproteinase-3
(MMP-3) was also enhanced. In addition, we observed higher levels of serum MMP-3 in HO-1M-KO mice compared with
control mice, suggesting the presence of systemic inflammation. Altogether, these findings demonstrate that myeloid HO-1
plays an anti-inflammatory role in the acute response to zymosan in vivo and suggest the interest of this target to regulate
inflammatory processes.
1. Introduction
Heme oxygenase (HO) catalyzes the oxidative degradation
of heme to carbon monoxide (CO), iron, and biliverdin
which is converted to bilirubin by biliverdin reductase [1].
HO-2 is constitutively expressed in the testes, brain, and
endothelium and would regulate normal physiological func-
tions while HO-1 is highly inducible by a wide range of
stimuli. HO-1 plays an important role in the antioxidant
defence system and iron homeostasis. In addition, HO-1
is involved in the regulation of different cell functions such
as proliferation, differentiation, and apoptosis (reviewed in
[2]). A wide range of evidence indicate that HO-1 regulates
the activation and function of different cell types driving
the inflammatory process and innate and adaptive immune
responses [3–8]. Therefore, HO-1 upregulation or adminis-
tration of its metabolites results in anti-inflammatory and
antioxidant effects in many disease models such as ath-
erosclerosis [9], cardiac ischemia/reperfusion injury [10], dia-
betes [11], inflammatory bowel disease [12], or rheumatoid
arthritis [4]. Conversely, the deletion of Hmox1 in mice
increases the severity of many experimental diseases, and
the incidence or severity of several human diseases are
associated with polymorphisms in the Hmox1 promoter
that regulates HO-1 expression [7, 13].
HO-1 knockout (Hmox1−/−) mice exhibit growth retar-
dation, anemia, proteinuria, hepatic and renal iron accumu-
lation, chronic inflammation, and reduced life span [14],
which are similar to the important alterations observed in
human HO-1 deficiency [15, 16]. Conditional deletion of
HO-1 could allow a more specific approach to study the role
of HO-1 in physiological and pathological processes. Previ-
ous works have shown that mice with selective deletion of
myeloid HO-1 (HO-1M-KO) do not exhibit any relevant
physiologic changes compared with wild-type animals, and
unlike HO-1−/− mice, they do not have enlarged spleens or
pathological abnormalities [17].
A great number of studies have been devoted to assess
HO-1 biological effects, in contrast with the relatively few
investigations using targeted approaches to specifically focus
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on myeloid HO-1. Previous reports have indicated that
myeloid HO-1 may be a protective pathway against renal
ischemia/reperfusion injury [18] or autoimmune central
nervous system diseases. Therefore, genetic ablation of
myeloid HO-1 enhances the infiltration of macrophages
and Th17 cells into the central nervous system resulting
in aggravation of experimental autoimmune encephalo-
myelitis [17]. In contrast, other works have shown that
macrophage conditional HO-1 deletion evokes resistance
to inflammation and metabolic disease [19], and myeloid
HO-1 would not play a main role in lung inflammation
induced by lipopolysaccharide [20]. It is therefore apparent
that more studies are necessary to understand the role of
myeloid HO-1 in inflammatory conditions.
Zymosan particles are recognized by the innate immune
system and induce inflammatory signals through Toll-like
receptors TLR2 and TLR6 leading to the production of
a variety of inflammatory mediators [21]. The zymosan-
induced mouse air pouch (MAP) is a widely used experi-
mental model useful to dissect the inflammatory response.
Besides, myeloid cells play an important role in zymosan-
induced inflammation which makes this stimulus appropri-
ate to characterize the contribution of myeloid HO-1. The
aim of this work was to investigate in vivo whether myeloid
HO-1 deletion could affect key steps of the early inflamma-
tory response in the zymosan-induced MAP.
2. Materials and Methods
2.1. Animals. All studies were performed in accordance
with European Union regulations for the handling and
use of laboratory animals. All the animal experiments were
approved by the Institutional Animal Care and Use Com-
mittee of the University of Valencia, Spain. Mice were
housed and cared for by the veterinary staff in accredited
facilities and were routinely screened for health status.
Hmox1FL/FL (129.B6-Hmox1tm1.1Gkl/FlmgEM: 10935)mice
were obtained from Alexander Fleming Biomedical Sciences
Research Center, Vari, Greece, and crossed with LysMCre
(B6.129P2-Lyz2tm1(cre)Ifo/CgnCnrmEM:01145)mice from
EMMA (European Mouse Mutant Archive) Repository,
Istituto Biologia Cellulare CNR, Monterotondo Scalo, Italy,
and MGC Stiftung (Mouse Genetics Cologne (MGC)
Foundation, Munich, Germany). Genotyping of mice was
performed using the KAPA Mouse Genotyping Kit (KAPA
Biosystems, Boston, MA, USA). Primers used for real-time
PCR were as follows: Hmox1 (F 5′-AGGGGAAGAAGACT
CATCGA-3′, R 5′-AGAAGGCTCGGAGGTTAAAT-3′),
LysMCre (F 5′-CGAGTGATGAGGTTCGCAAG-3′, R 5′-
TGAGTGAACGAACCTGGTCG-3′), and LysMWT (F 5′-
GCATTGCAGACTAGCTAAAGGCAG-3′, R 5′-GTCGGC
CAGGCTGACTCCATAG-3′). For Hmox1, 1 cycle was
for 4min in 94°C; 1 cycle for 45 sg in 52°C; 30 cycles for
45 sg in 93°C, 45 sg in 52°C, and 1min in 72°C; and 1 cycle
for 10min in 72°C. For Cre, 1 cycle was for 2min in 95°C;
45 cycles for 30 sg in 95°C, 30 sg in 58°C, 90 sg in 72°C;
and 1 cycle for 10min in 72°C. The products, 545 bp
(Hmox1FL), 387 bp (Hmox1WT), 390 bp (LysMCre), and
428 bp (LysMWT) were analyzed with the Agilent Bioanaly-
zer 2100 (Agilent Technologies Spain, Madrid). To con-
firm the suppression of HO-1, we isolated peritoneal
macrophages from LysMCre/+Hmox1FL/FL (HO-1M-KO) and
Hmox1FL/FL (control) mice and analyzed HO-1 expression
by immunocytochemistry and flow cytometry. Macrophages
were obtained by peritoneal lavage with saline. HO-1 expres-
sion was assessed in adherent cells stimulated with 0.1μg/ml
phorbol 12-myristate 13-acetate (Sigma-Aldrich, St. Louis,
MO, USA) for 18 h at 37°C. Cells were fixed with 2% parafor-
maldehyde (5min, 4°C) and permeabilized with 0.1% Triton
X-100 for 10min. After blocking (10% bovine serum
albumin), anti-HO-1 polyclonal antibody (Enzo Life Sciences
Inc.) was incubated overnight at 4°C. Unbound antibody was
removed with phosphate-buffered saline, and the secondary
fluorescent antibody (anti-rabbit IgG, R&D Systems, Minne-
apolis, MN, USA) was incubated for 30min. Macrophages
were observed with a fluorescence microscope (Leica DM
IL LED, Solms, Germany). Cells were also analyzed by flow
cytometry with the anti-mouse CD16/CD32 antibody for
blockade (eBioscience, Thermo Fisher Scientific, Waltham,
MA, USA) followed by anti-F4/80-APC, anti-Ly-6G (Gr-1)-
PE (eBioscience, Thermo Fisher Scientific), and HO-1-
FITC mAb (Enzo Life Sciences Inc.) using FACScan and Cell
Quest Pro (Becton Dickinson, Madrid, Spain).
2.2. Mouse Air Pouch (MAP). Mice were maintained at
21°C± 2°C on a 12 h light/dark cycle with feed and water
ad libitum. Male HO-1M-KO and control mice between
10 and 12 weeks were used in these experiments. To cre-
ate the MAP, 10ml of sterile air was injected subcutane-
ously into the dorsal area of the mouse (day 0). Three
days later, 5ml of sterile air was injected (day 3), and
six days after the initial injection of sterile air (day 6),
1ml of saline buffer or 1ml of 1% w/v zymosan (Sigma-
Aldrich) in saline buffer was injected into the air pouch
[22]. At 18h after zymosan stimulation, blood was col-
lected from the retroorbital venous plexus, mice were
sacrificed by cervical dislocation, and the exudate of the
air pouch was collected. Cells present in exudates were
measured with a Coulter counter and differential counting
was also performed. Exudates were centrifuged at 10,000×g
for 5min at 4°C. Supernatants were then collected and frozen
at −80°C to measure the levels of inflammatory and catabolic
mediators. Cell pellets were lysed and used for HO-1
determination by western blotting.
2.3. Determination of Inflammatory Mediators. Interleukin-
1β (IL-1β) and tumor necrosis factor-α (TNFα) were
measured by enzyme-linked immunosorbent assay (ELISA)
(R&D Systems, Minneapolis, MN, USA) with a range detec-
tion of 15.6–1000 pg/ml and 31.2–2000 pg/ml, respectively.
C-X-C motif chemokine ligand 1 (CXCL-1) ELISA was
from PromoKine (Heidelberg, Germany) with a sensitivity
of 8.0 pg/ml. MMP-3 levels were measured by ELISA (R&D
Systems Europe Ltd., Abingdon, UK), with sensitivity of
19.0 pg/ml. The eicosanoid prostaglandin E2 (PGE2) was
determined by radioimmunoassay [23].
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2.4. Western Blotting. Cell pellets from the air pouch exudates
were resuspended in a buffer pH7.46 containing 10mM
HEPES, 1mM EDTA, 1mM EGTA, 10mM KCl, 1mM
dithiothreitol, 5mM NaF, 1mM Na3VO4, 1μg/ml leupeptin,
0.1μg/ml aprotinine, and 0.5mM phenylmethyl sulfonyl
fluoride and were sonicated (3× 10 sec) and centrifuged at
10,000×g for 10min at 4°C. Supernatants were collected
and protein concentration was evaluated by the DC protein
reagent (Bio-Rad, Hercules, CA, USA). Proteins (30μg)
were separated by SDS/PAGE (12.5%) and transferred to
PVDF membranes. Membranes were blocked with 5%
nonfat dry milk and incubated with specific polyclonal
antibody against HO-1 (1/1000) (Enzo Life Sciences Inc.,
Farmingdale, NY, USA) or β-actin (1/5000, Sigma-Aldrich)
for 2 h at room temperature. Finally, membranes were
incubated with peroxidase-conjugated polyclonal goat anti-
rabbit IgG (1/5000, Dako, Glostrup, Denmark) and the
immunoreactive bands were visualized by enhanced chemi-
luminescence (ECL®, GE Healthcare, Buckinghamshire,
UK) using an AutoChemi image analyser (UVP Inc., Upland,
CA, USA). Band intensity was analysed by optical densi-
tometry using ImageJ analysis software (NIH, USA). Band
densities were corrected for background, and protein levels
were normalized against β-actin.
2.5. Statistical Analysis. The data were presented as
mean± SD. Normal distribution of data was assessed by the
Shapiro-Wilk normality test. Two-way analysis of variance
(ANOVA) followed by Sidak’s multiple comparisons test,
or unpaired t-test was performed. All statistical analyses were
performed using GraphPad Prism version 7.00 for Windows
(GraphPad Software, San Diego, CA, USA). A P value lower
than 0.05 was considered to indicate statistical significance.
3. Results
3.1. Confirmation of HO-1 Deletion in Mouse Peritoneal
Macrophages. Hmox1FL/FL mice were crossed with LysMCre
knockin mice for deletion of HO-1 in myeloid cells. The
LysMCre transgene mediates the excision of loxP-flanked
sequences in these cells [24]. We assessed HO-1 protein
expression in mouse peritoneal macrophages by immunocy-
tochemistry (Figure 1(a)) and flow cytometry (Figure 1(b)).
HO-1 expression was observed in macrophages from
Hmox1FL/FL (control) but not in LysMCre/+Hmox1FL/FL
(HO-1M-KO) mice, thus confirming the efficient deletion of
myeloid HO-1.
3.2. Cell Migration into the MAP. Zymosan induces cell acti-
vation and production of a wide range of proinflammatory
mediators that are quickly released into the inflammatory
milieu. As a consequence, there is an important leukocyte
influx into the air pouch. We have previously reported that
migrating cells are predominantly neutrophils. They repre-
sent about 88-89% of cells present in air pouch exudates
[25]. The interaction between treatment (saline or zymosan)
and genotype (control or HO-1M-KO) was significant for
cell migration (F = 10 67, P = 0 0039). Figure 2(a) shows
that zymosan induced a significant cell migration into
the air pouch compared with saline-injected air pouches
in both control and HO-1M-KO mice. It is interesting to
note that inflammatory cell accumulation in air pouch
exudate induced by zymosan was significantly higher in
HO-1M-KO mice compared with control mice (11.3± 3.9
versus 5.1± 1.7× 106 cells/ml). In this experimental model,
there is a time-dependent increase in HO-1 expression in
the cells migrating to the air pouch exudate [26]. We
assessed HO-1 protein expression in these migrating cells
and observed a high level in cells from control animals
whereas a very reduced expression was present in cells
from HO-1M-KO mice (Figure 2(b)). HO-1 protein was
not completely suppressed in this last group as some non-
myeloid cells are also present in exudates [25].
3.3. Proinflammatory Mediators in Air Pouch Exudate. There
were no significant differences in levels of proinflammatory
mediators between control and HO-1M-KO mice in the
absence of zymosan stimulation. The proinflammatory cyto-
kines IL-1β and TNFα play an important role in the response
induced by zymosan (Figures 3(a) and 3(b)). Our results
indicate that IL-1β and TNFα production in response to
zymosan depended on genotype (F = 19 36, P = 0 0003 and
F = 5 27, P = 0 0472, resp.). Zymosan elicited a higher
IL-1β level in HO-1M-KO mice (1582.0± 40.3 pg/ml) com-
pared with control mice (1185.0± 191.1 pg/ml). Similarly,
TNFα levels in the presence of zymosan were enhanced
in HO-1M-KO mice (521.1± 175.0 pg/ml) with respect to
control animals (290.8± 49.02 pg/ml). In addition, the
interaction between treatment and genotype was significant
for the production of the chemokine CXCL-1 (F = 8 13,
P = 0 0102). The levels of CXCL-1 in inflammatory exudates
were increased by zymosan administration in both control
and HO-1M-KO mice (Figure 4(a)) although there was no
significant difference between them (9.83± 1.0 and 8.9±
1.0 pg/ml, resp.). PGE2 is an important proinflammatory
mediator in this experimental model. We found that PGE2
production induced by zymosan depended on genotype
(F = 12 11, P = 0 0083). Figure 4(b) shows that zymosan
stimulation resulted in high levels of this eicosanoid in
the inflammatory exudate in both control and HO-1M-KO
mice. The production of PGE2 in HO-1
M-KO mice (109.0±
16.1 ng/ml) was significantly higher than that of control
animals (42.7± 21.9 ng/ml).
3.4. Levels of MMP-3 in Air Pouch Exudate and Serum. There
was a significant interaction between treatment and genotype
for MMP-3 levels in air pouch exudate and serum (F = 16 75,
P = 0 0006 and F = 58 93, P < 0 0001, resp.). MMP-3 levels in
the air pouch exudate were enhanced by the inflammatory
response to zymosan (Figure 5(a)), and we observed a stron-
ger effect in HO-1M-KO mice (153.5± 54.8 ng/ml) compared
with controls (61.3± 28.6 ng/ml). We also assessed MMP-3
levels in serum as a marker of systemic inflammation. As
shown in Figure 5(b), in the absence of zymosan stimula-
tion, serum levels of MMP-3 were significantly higher in
HO-1M-KO mice (50.1± 9.9 versus 11.6± 5.4 ng/ml). Zymo-
san injection did not increase serum MMP-3 in the control
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group (10.6± 2.5 ng/ml) but exerted a dramatic effect in
HO-1M-KO mice (151.2± 32.5 ng/ml).
4. Discussion
Myeloid cells have important roles in both innate and
adaptive immune responses [27]. Studies in mice with
specific deletion of HO-1 in myeloid cells have revealed the
contribution of HO-1 to the maturation and differentiation
of monocytes/macrophages. In addition, HO-1 is relevant
for cell functions such as phagocytic activity and bacterial
clearance. These actions of HO-1 can be reproduced by exog-
enously applied CO [28, 29] which exerts anti-inflammatory
and proresolution effects [30]. We have demonstrated using
HO-1M-KO mice that myeloid-restricted deletion of HO-1
potentiates the inflammatory response to zymosan. These
results are consistent with our previous data showing that
induction of HO-1 exerts anti-inflammatory effects in this
experimental model [26]. In the current study, we have
shown that HO-1M-KO mice exhibit increased neutrophil
infiltrates in response to zymosan administration. This effect
on cell migration was higher than that observed in another
inflammatory model using HO-1+/− and HO-1−/− mice
[13]. Our results thus indicate that myeloid HO-1 plays an
important role in the regulation of neutrophil migration
and the production of inflammatory and catabolic mediators
during the acute response to zymosan in vivo. In particular,
we observed an increased production of IL-1β, TNFα,
PGE2, and MMP-3 in the inflammation focus. This is in
contrast to the observed in vitro response of mouse macro-
phages to lipopolysaccharide, where myeloid HO-1 is not
essential for TLR4-induced nuclear factor-κB activation and
proinflammatory cytokine production but is required for
TLR4/TLR3/interferon regulatory factor 3-induced produc-
tion of interferon-β [17].
Proinflammatory cytokines and elevated levels of PGE2
promote the production of MMPs. These enzymes degrade
































































Figure 1: Expression of HO-1 in peritoneal macrophages fromHO-1M-KO and control mice. (a) Immunocytochemistry for HO-1 expression.
Representative images. (b) Flow cytometry. F4/80-positive cells expressed HO-1 in control mice but not in HO-1M-KO mice.
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regulation of proinflammatory mediators. In particular,
MMP-3 (stromelysin-1) is able to cleave and activate other
MMPs such as collagenases [31] and the cytokines TNFα
and IL-1β. In addition, MMPs such as MMP-3 can
induce macrophage secretion of TNFα leading to
cyclooxygenase-2 induction and PGE2 production which in
turn increases MMP expression. This nexus between MMPs
and prostanoids may be relevant in the pathogenesis of
chronic inflammatory diseases and cancer [32].
There are a number of ways in which MMP-3 partici-
pates in tissue destruction. Studies in MMP-3 knockout mice
have shown the key role of this MMP in cartilage lesion and
the contribution of synovial macrophages to MMP-mediated
damage [33]. We have previously shown that HO-1 over-
expression downregulates MMP-3 and other degradative
enzymes in articular cells such as synoviocytes [5]. In
the current study, we have demonstrated that deficiency
in myeloid HO-1 enhances the induction of MMP-3 by
zymosan in vivo, which may contribute to the inflammatory
amplification process involving cytokines, eicosanoids, and
proteases which results in tissue damage.
Interestingly, HO-1M-KO mice showed high levels of
serum MMP-3 even in the absence of zymosan treatment,
which indicates the presence of a systemic inflammatory
response in these animals. In fact, serum MMP-3 levels
are related to inflammation and tissue damage in condi-
tions such as rheumatoid arthritis, where synovial macro-
phages are crucial in early MMP activity and serum
MMP-3 may be a biomarker of disease activity and predictor
of joint destruction [34, 35]. Therefore, our data suggest that








































Figure 3: Levels of proinflammatory cytokines in MAP exudate. IL-1β (a) and TNFα (b) were measured by ELISA. Results are shown as
mean± SD (n = 6); ++P < 0 01, +++P < 0 001, and ++++P < 0 0001 with respect to saline-injected group; ∗P < 0 05 and ∗∗∗∗P < 0 0001








































Figure 2: Cell migration into the MAP. (a) Cell numbers in the exudate, mean± SD (n = 6). (b) Immunoblot for HO-1 expression in cells of
the exudate. Representative images and rate of HO-1/β-actin; ++P < 0 01 and ++++P < 0 0001 with respect to saline-injected group; ∗P < 0 05
and ∗∗∗P < 0 001, compared to control mice (a: two-way ANOVA followed by Sidak’s test; b: unpaired t-test).
5Oxidative Medicine and Cellular Longevity
In conclusion, this study has revealed that myeloid HO-1
mediates protection against the inflammatory response to
zymosan in vivo. These data point to new directions in
therapeutic interventions that may potentially limit the
deleterious effects of excessive inflammation.
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